As of 2024-09-14, the Relative Valuation of Revance Therapeutics Inc (RVNC) is (17.80) USD. This relative valuation is based on P/E multiples. With the latest stock price at 6.55 USD, the upside of Revance Therapeutics Inc based on Relative Valuation is -371.8%.
The range of the Relative Valuation is (0.83) - (28.98) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.3x - 10.5x | 5.4x |
| Forward P/E multiples | 0.3x - 14.7x | 7.5x |
| Fair Price | (0.83) - (28.98) | (17.80) |
| Upside | -112.6% - -542.4% | -371.8% |
| Date | P/E |
| 2024-09-13 | -2.37 |
| 2024-09-12 | -2.38 |
| 2024-09-11 | -2.38 |
| 2024-09-10 | -2.38 |
| 2024-09-09 | -2.38 |
| 2024-09-06 | -2.38 |
| 2024-09-05 | -2.38 |
| 2024-09-04 | -2.38 |
| 2024-09-03 | -2.39 |
| 2024-08-30 | -2.38 |
| 2024-08-29 | -2.38 |
| 2024-08-28 | -2.38 |
| 2024-08-27 | -2.38 |
| 2024-08-26 | -2.38 |
| 2024-08-23 | -2.39 |
| 2024-08-22 | -2.39 |
| 2024-08-21 | -2.39 |
| 2024-08-20 | -2.39 |
| 2024-08-19 | -2.40 |
| 2024-08-16 | -2.40 |
| 2024-08-15 | -2.39 |
| 2024-08-14 | -2.38 |
| 2024-08-13 | -2.39 |
| 2024-08-12 | -2.39 |
| 2024-08-09 | -1.28 |
| 2024-08-08 | -1.07 |
| 2024-08-07 | -1.02 |
| 2024-08-06 | -1.12 |
| 2024-08-05 | -1.11 |
| 2024-08-02 | -1.16 |
| 2024-08-01 | -1.22 |
| 2024-07-31 | -1.37 |
| 2024-07-30 | -1.34 |
| 2024-07-29 | -1.37 |
| 2024-07-26 | -1.42 |
| 2024-07-25 | -1.36 |
| 2024-07-24 | -1.42 |
| 2024-07-23 | -1.57 |
| 2024-07-22 | -1.45 |
| 2024-07-19 | -1.32 |
| 2024-07-18 | -1.32 |
| 2024-07-17 | -1.43 |
| 2024-07-16 | -1.54 |
| 2024-07-15 | -1.38 |
| 2024-07-12 | -1.30 |
| 2024-07-11 | -1.18 |
| 2024-07-10 | -1.05 |
| 2024-07-09 | -1.05 |
| 2024-07-08 | -1.01 |
| 2024-07-05 | -0.97 |